Anlon Healthcare Limited is a research-oriented pharmaceutical manufacturing company engaged primarily in Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. Its products are used as inputs for finished pharmaceutical formulations and serve customers in regulated and other markets. Growth in pharmaceutical outsourcing and demand for quality API and intermediate manufacturing provides long-term opportunities. Regulatory compliance, product approvals, customer concentration, raw-material costs, capacity utilization, pricing pressure, and global pharmaceutical demand remain important considerations.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|
| ₹1,434 cr | — | — | 11.1 | 2.42 | 6.23 | 47.4% | 0.19 | ₹-79 cr | 30.7 | 0.44 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Dec 2025 | 36 | 5 | 0.11 | — | — | 14.5% |
| Sep 2025 | 52 | 9 | 0.22 | — | — | 17.8% |
| Jun 2025 | 33 | 4 | 0.22 | — | — | 10.7% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | — Not assessable |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | — Not assessable |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | — Not assessable |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✓ Close above the 50-day ✓ At least 25% above the 52-week low · low 10.82 ✗ Within 25% of the 52-week high · high 36.39 ✓ RS percentile 70 or more · RS 98 Trend template - the gate, measured: a modest 21-day edge. | 7/8 | 7 of 8 |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | — C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✗ N within 15% of the 52-week high · high 36.39 ✓ S more volume on up days than down days (50 sessions) · 5.48x ✓ L RS percentile 80 or more · RS 98 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 3/4 | Average |
| Darvas | ✓ Box top confirmed (3 sessions below the new high) · top 37.24 ✓ Box bottom confirmed (3 sessions holding) · bottom 25.51 ✗ Close above the box top · close 26.97 ✗ Volume at least 1.5x its 50-day average · 0.3x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 36/100 | In box |
| Turtle | ✗ Close above the prior 55-session high · 37.24 ✗ Close above the prior 20-session high · 37.24 ✗ Close below the prior 20-session low · 22.11 Donchian channel breakout - the Turtle traders' entry. | No signal | |
| Graham | ✗ Price at or below the Graham number · Graham number 15.35 ✓ P/E 15 or less · P/E 11.1 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 6.23 ✓ Current ratio 2 or more · 2.87 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 57/100 | Expensive |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AHCL this stock | +17.8 | +79.8 | +86.2 | +112.4 | — | — | 11.1 | 6.23 | 47.4 | — | — | 0.19 | 30.7 | 1,434 | — | — | 2.4 | 0.44 |
| SAKAR | -21.8 | +2.7 | +51.5 | +162.7 | +158.4 | +464.3 | 57.0 | 6.33 | 10.0 | 12.9 | — | 0.17 | 30.8 | 2,054 | 272 | 36 | 16.2 | 0.69 |
| KOVAI | -5.6 | -0.9 | +7.0 | +128.0 | +118.8 | +256.0 | 25.5 | 4.87 | 19.4 | — | — | — | — | 6,429 | — | — | 234.2 | — |
| VIJAYA | -12.2 | +2.5 | +33.7 | +37.9 | +134.0 | +143.8 | 75.1 | 14.71 | 19.7 | 30.3 | — | 0.00 | 39.6 | 14,078 | 857 | 188 | 18.2 | 0.54 |
| ENTERO | -13.2 | +26.4 | +18.2 | +35.9 | — | — | 52.2 | 3.88 | 6.7 | 10.7 | — | 0.34 | 26.4 | 6,545 | 7,128 | 168 | 28.8 | 0.36 |
| AMANTA | -13.3 | -0.0 | +21.9 | +34.8 | — | — | 39.6 | 2.57 | — | — | — | 1.06 | — | — | 291 | 15 | 4.2 | 0.73 |
| YATHARTH | -14.8 | +14.4 | +30.6 | +19.8 | +147.7 | — | 51.6 | 5.18 | 10.0 | 12.4 | — | 0.14 | 30.2 | 9,356 | 1,334 | 174 | 18.8 | 0.88 |
| LALPATHLAB | -2.8 | +8.9 | +30.0 | +18.6 | +47.0 | -0.3 | 56.8 | 12.32 | 21.6 | 29.1 | — | 0.00 | 36.2 | 30,900 | 2,891 | 546 | 32.5 | 0.41 |
| THYROCARE | -15.3 | -15.2 | +19.9 | +13.6 | +151.4 | +22.7 | 42.6 | 12.80 | 28.8 | 37.8 | — | 0.00 | 28.2 | 7,497 | 876 | 176 | 11.1 | 0.47 |
| STARHEALTH | -0.9 | -6.7 | +7.0 | +7.6 | -8.9 | — | 35.7 | 3.15 | 8.9 | — | — | — | — | 31,904 | — | — | 15.3 | 0.41 |
| METROPOLIS | -13.1 | -9.5 | +9.2 | +7.1 | +37.5 | -24.5 | 53.4 | 7.11 | 13.4 | 19.6 | — | 0.01 | 26.3 | 10,763 | 1,710 | 203 | 9.7 | 0.43 |